

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approvals for drug production and registration for Magnesium Sulfate Injection (20ml: 10g, 10ml: 5g and 2ml: 1g) and Vortioxetine Hydrobromide Tablets (10mg) from the National Medical Products Administration of China, being under type 3 chemical drug and type 4 chemical drug respectively, and regarded as passing the consistency evaluation.

As an anticonvulsant drug, Magnesium Sulfate Injection is a mainly used in pregnancy-induced hypertension for the treatment of pre-eclampsia and eclampsia by reducing blood pressure. Vortioxetine Hydrobromide Tablets is mainly used for the treatment of depression in adults.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
*Executive Director and Company Secretary*

Hong Kong, 16 January 2024

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.*